Supplementary Figure S1. Lymphocyte counts from Clinical Activity and Safety of Combination Therapy with Temsirolimus and Bevacizumab for Advanced Melanoma: A Phase II Trial (CTEP 7190/Mel47)
Year: 2023
Type: supplementary-materials
Abstract: Lymphocyte counts for all patients on study - detail
Authors: Craig L. Slingluff, Gina R. Petroni, Kerrington R. Molhoek, David L. Brautigan, Kimberly A. Chianese-Bullock, Amber L. Shada, Mark E. Smolkin, Walter C. Olson, Alison Gaucher, Cheryl Murphy Chase, William W. Grosh, Geoffrey R. Weiss, Aubrey G. Wagenseller, Anthony J. Olszanski, Lainie Martin, Sofia M. Shea, Gulsun Erdag, Prahlad Ram, Jeffrey E. Gershenwald, Michael J. Weber
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4361909253